Results for this period
Full year1 June 2025 to 31 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The number of examinations and surgeries and the number of facilities under SPD contracts increased, and the minimally invasive treatment materials and dialysis fields grew, while demand for capital investment in radiation equipment, diagnostic imaging equipment and other products declined. Selling, general and administrative expenses increased due to investments in human capital, ¥32 million in expenses for the grant of restricted stock, security- and DX-related expenses, and higher depreciation expenses for molds and other assets used for BreastScan.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2025 to 31 May 2026 |
| Net Sales | 64,149 Millions of yen (YoY -0.5%) |
| Operating profit | 737 Millions of yen (YoY -12.1%) |
| Ordinary income | 877 Millions of yen (YoY -3.5%) |
| Profit attributable to owners of the parent | 648 Millions of yen (YoY +5.1%) |
| Net income per share | ¥258.56 |
| Operating Margin | 1.1% |
| Equity ratio | End of the current fiscal period 34.6% / End of previous period 32.6% |
| Total assets | 27,089 Millions of yen |
| Net assets | 9,360 Millions of yen |
| Cash flows from operating activities | 88 Millions of yen |
| Cash flows from investing activities | -1,322 Millions of yen |
| Cash flows from financing activities | -337 Millions of yen |
| Cash and cash equivalents at end of period | 4,127 Millions of yen |
| Full-year earnings forecast | Net Sales 69,794 Millions of yen (YoY +8.8%) / Operating profit 833 Millions of yen (YoY +13.1%) / Ordinary income 855 Millions of yen (YoY -2.4%) / Profit attributable to owners of the parent 553 Millions of yen (YoY -14.6%) |
| Annual Dividend Forecast | ¥107.00 → ¥65.00（-39.3%） |
| Payout ratio | 41.4% |
| Shareholder Return Policy | Basically based on a consolidated dividend payout ratio of 30% |
| Segment revenue | Medical device sales 64,201 Millions of yen (YoY -0.4%), Medical Equipment Manufacturing and Sales 210 Millions of yen (YoY -4.4%), Medical Mall Business 74 Millions of yen (YoY +1.6%) |
| Segment profit | Medical device sales 2,132 Millions of yen (YoY -3.0%), Medical Equipment Manufacturing and Sales -185 Millions of yen, Medical Mall Business 7 Millions of yen (YoY +37.1%) |
| Depreciation and amortization | 215 Millions of yen |
| Impairment loss | 9 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of allowance for doubtful accounts 50 Millions of yen, Gain on revision of retirement benefit plans 13 Millions of yen / Extraordinary loss Impairment Losses 9 Millions of yen, Loss on sale of shares in a subsidiary 2 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name 株式会社イーディライト |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 2,553,000 Shares |
| Treasury Shares at Period-End | 9,771 Shares |
| Factors Behind Changes in Business Performance | The number of examinations and surgeries and the number of facilities under SPD contracts increased, and the minimally invasive treatment materials and dialysis fields grew, while demand for capital investment in radiation equipment, diagnostic imaging equipment and other products declined. Selling, general and administrative expenses increased due to investments in human capital, ¥32 million in expenses for the grant of restricted stock, security- and DX-related expenses, and higher depreciation expenses for molds and other assets used for BreastScan. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales declined because demand for capital investment in radiation equipment, diagnostic imaging equipment and other products fell below the previous fiscal year, despite increases in the number of examinations and surgeries, the number of facilities under SPD contracts, and growth in minimally invasive treatment materials and the dialysis field. Operating income declined because selling, general and administrative expenses increased due to investments in human capital, ¥32 million in expenses for the grant of restricted stock, security- and DX-related expenses, and higher depreciation expenses for molds and other assets used for BreastScan. For the next fiscal year, the Company expects ordinary income and net income to decline due to higher costs associated with investments in human capital and the renovation of its logistics center.